Dive Deeper into COVID-19 Research with SMC™ Kit

For COVID-19 researchers, accurate characterization of humoral immunity is of great importance. The unparalleled sensitivity and resolution of the new SMC™ SARS-CoV-2 RBD IgG kit can improve the value of data generated from crucial COVID-19 related vaccine development, epidemiology, and surveillance studies.

The new SMC™ SARS-CoV-2 RBD IgG kit can be used to:

• Study immunity throughout infection

• Evaluate candidate vaccine and therapeutic efficacy

• Characterize differences in SARS-CoV-2 response in various populations.

Explore Merck’s extensive portfolio of highly verified SMC™ high sensitivity cytokine assays for characterization of SARS-CoV-2 effector immunity and be on your way to the next COVID-19 research breakthrough.

SMCxPRO™ Immunoassay Instrument & Kits

With the SMCxPRO™ platform you can detect extremely low-levels of established disease biomarkers, capturing concentrations down to the femtogram/mL level, and as a result monitor small changes in protein concentrations to accurately measure biomarkers associated with disease progression. In addition, the small sample volume requirements allow you to conserve valuable samples, reduce program costs and improve productivity.

Webinar: IgG Antibodies Against SARS-CoV-2

There’s still time to register! The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a global pandemic of COVID-19. In this webinar, Mary Young shares the results from the evaluation of the MILLIPLEX® SARS-CoV-2 Antigen Panels. These panels can measure IgG, IgA, and IgM antibody levels against SARS-CoV-2 spike proteins (S1 and S2), receptor binding domain (RBD), and nucleocapsid protein (N) using less than 1 µL of plasma from patients tested for COVID-19.

Date: Thursday, January 28, 2021

Time: 19:00 AST | 20:00 GST